



PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251XC001673 AGE

PATIENT ID : GOMAF180300251

CLIENT PATIENT ID: 012403180029

ABHA NO :

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00 RECEIVED :18/03/2024 11:46:51

REPORTED :18/03/2024 16:36:09

rest report status Filiai results piological reference filiteryal v	Test Report Status Final	Results	Biological Reference Interval	Units
---	--------------------------	---------	-------------------------------	-------

ни	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	10.4 Low	12.0 - 15.0	g/dL
METHOD: CYANIDE FREE DETERMINATION RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.36	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	5.20	4.0 - 10.0	thou/μL
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	280	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	34.4 Low	36 - 46	%
METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	79.0 Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	23.8 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	30.2 Low	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	15.6 High	11.6 - 14.0	%
MENTZER INDEX	18.1		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	10.2	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	55	40 - 80	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	37	20 - 40	%
MONOCYTES	06	2 - 10	%

Dr. Akansha Jain



Page 1 Of 17

View Details





Consultant Pathologist







PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251 CLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX :24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED: 18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	02	1 - 6	%
BASOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	2.86	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	1.92	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.31	0.2 - 1.0	thou/μL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED PARAMETER	0.10	0.02 - 0.50	thou/μL
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.5		

Interpretation(s)
BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. Howeverafter 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms tochange from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist**



Page 2 Of 17











PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : 0251XC001673

PATIENT ID : GOMAF180300251

CLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

%

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.5

Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 111.2 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist



Page 3 Of 17

View Details

View Report







PATIENT NAME: GOMATI BAI MEENA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XC001673 PATIENT ID

: GOMAF180300251 CLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX : 24 Years Female :18/03/2024 11:12:00 DRAWN

RECEIVED: 18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status Final Results **Biological Reference Interval** Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

mm at 1 hr E.S.R 0 - 20

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, and 2 time well-controlled type 2 diabetic patients, and 2 time well-controlled type 2 diabetic patients to determine whether a patients meter control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

- HbA1c Estimation can get affected dueto:

 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridgina, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
ERYTHROCYTE SEDIMENTATION RATE (ESP), EDTA BLOOD-**TEST DESCRIPTION**:
Erythrocyte sedimentation rate(ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate offall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that àre present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for asystemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm/hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain **Consultant Pathologist** Page 4 Of 17











PATIENT NAME: GOMATI BAI MEENA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251 CLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX :24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED: 18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status Final Results **Biological Reference Interval** Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified byantigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.'

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist**



Page 5 Of 17









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-

AAKRIT LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251XC001673 AGE

PATIENT ID : GOMAF180300251

CLIENT PATIENT ID: 012403180029

ABHA NO :

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00 RECEIVED :18/03/2024 11:46:51

REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u> Results Biological Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	91	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	81	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDL			
CHOLESTEROL, TOTAL	146	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD: CHOLESTEROL OXIDASE TRIGLYCERIDES	62	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD: LIPASE/GPO-PAP NO CORRECTION HDL CHOLESTEROL	45	< 40 Low >/=60 High	mg/dL
METHOD: DIRECT CLEARANCE METHOD CHOLESTEROL LDL	89	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL al
NON HDL CHOLESTEROL	101	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL)

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist





Page 6 Of 17



View Report









PATIENT NAME: GOMATI BAI MEENA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 ACCESSION NO: 0251XC001673 AGE

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251XC001673**PATIENT ID: GOMAF180300251

CLIENT PATIENT ID: 012403180029

ABHA NO :

AGE/SEX :24 Years Female DRAWN :18/03/2024 11:12:00 RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u> Results		Biological Reference Interval Units	
VERY LOW DENSITY LIPOPROTEIN	12.4	= 30.0 mg/dL</th	
CHOL/HDL RATIO	3.2 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	2.0	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category		
Extreme risk group	A.CAD with > 1 feature of high risk group	
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease	
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemi	a
High Risk	1. Three major ASCVD risk factors. 2. Dia	betes with 1 major risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL >1	90 mg/dl 5. Extreme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipopr	otein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors	
Low Risk	0-1 major ASCVD risk factors	
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ctors
1. Age $>$ or $=$ 45 year	s in males and $>$ or $= 55$ years in females	3 Current Cigarette smoking or tobacco use
2. Family history of p	remature ASCVD	4. High blood pressure
5. Low HDL		
	1 / / 1 1 1/1 / 1 1 1 1 1 1	11 7 17 1 0000

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

٠	tewer treatment goins and statin in	ittitution thi conoids bus	ed on the risk thtegori	es proposed by Err	I III 2020.
	Risk Group	Treatment Goals		Consider Drug T	herapy
		LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
	Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
		< OR = 30)	< OR = 60)		

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 17

View Details

View Report









Units

PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251

ABHA NO :

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

est Report	Status	Final

Results Biological Reference Interval

REF. DOCTOR: SELF

Extreme Risk Group Category B	<or 30<="" =="" th=""><th><or 60<="" =="" th=""><th>> 30</th><th>>60</th></or></th></or>	<or 60<="" =="" th=""><th>> 30</th><th>>60</th></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.37	0 - 1	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID BILIRUBIN, DIRECT METHOD: DIAZO WITH SULPHANILIC ACID	0.12	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT	0.25	0.1 - 1.0	mg/dL
METHOD: CALCULATED PARAMETER TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	7.8	6.4 - 8.2	g/dL
ALBUMIN	4.4	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.3	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	23	0 - 31	U/L
METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	14	0 - 31	U/L
ALKALINE PHOSPHATASE	60	39 - 117	U/L
METHOD: AMP OPTIMISED TO IFCC 37° C GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC)	11) 37° C	7 - 32	U/L
LACTATE DEHYDROGENASE	291	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 10 5.0 - 18.0 mg/dL

METHOD: UREASE KINETIC

Dr. Akansha Jain Consultant Pathologist



Page 8 Of 17

View Details

View Report









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF

ACCESSION NO : **0251XC001673**PATIENT ID : GOMAF180300251

| | ICLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status Final Results Biological Reference Interval Units

CREATININE, SERUM

CREATININE 0.80 0.6 - 1.2 mg/dL

METHOD: ALKALINE PICRATE NO DEPROTEINIZATION

BUN/CREAT RATIO

BUN/CREAT RATIO 12.50

METHOD: CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID **2.3 Low** 2.4 - 5.7 mg/dL

METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.8 6.4 - 8.3 g/dL

METHOD: BIURET REACTION, END POINT

ALBUMIN, SERUM

ALBUMIN 4.4 3.8 - 4.4 g/dL

METHOD: BROMOCRESOL GREEN

GLOBULIN

GLOBULIN 3.4 2.0 - 4.1 g/dL

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain Consultant Pathologist Page 9 Of 17





View Details

View Report









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251 CLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX :24 Years Female DRAWN :18/03/2024 11:12:00 RECEIVED :18/03/2024 11:46:51

REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
SODIUM, SERUM METHOD: ION-SELECTIVE ELECTRODE	140.4	137 - 145	mmol/L
POTASSIUM, SERUM	4.90	3.6 - 5.0	mmol/L
METHOD: ION-SELECTIVE ELECTRODE CHLORIDE, SERUM METHOD: ION-SELECTIVE ELECTRODE	106.0	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake, prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chron c respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosterorism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's discase, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide,androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION
Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g. galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate withhome glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

Dr. Akansha Jain **Consultant Pathologist** Page 10 Of 17













PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251

CLIENT PATIENT ID: 012403180029 ABHA NO

AGE/SEX DRAWN

: 24 Years Female :18/03/2024 11:12:00

RECEIVED: 18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status Final Results **Biological Reference Interval** Units

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Filirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in/Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin ja so elevated more than unconjugated (indirect) bilirubin is elevated more than unconjugated (indirect) bilirubin ja so elevated more than unconjugated (indirect) bilirubin ja so elevated more than unconjugated (indirect) bilirubin in ja so elevated more than unconjugated (indirect) bili attaches sugar molecules to bilirubin.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may bedue to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms

disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Prerenal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liverdisease, SIADH.

Causes of decreased level include Liverdisease, SIADH.

CREATININE, SERUM-Higher than normal level may be dueto:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss ofbody fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be dueto: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns Glomerulogenbritis, Liverdisease, Malabsorpting, Malputrition, Nephrotic

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liverdisease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liverdisease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or décreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain **Consultant Pathologist** Page 11 Of 17











PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XC001673

РАТІЕНТ ID : GOMAF180300251

ICLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE SLIGHTLY HAZY

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 5.0 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY

1.010

1.003 - 1.035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NOT DETECTED

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE

NOT DETECTED

NEGATIVE

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD : SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NOT DETECTED

METHOD: PEROCIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE **DETECTED** NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) **20-30** 0-5 /HPF

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain Consultant Pathologist



Page 12 Of 17



View Report









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251

I CLIENT PATIENT ID: 012403180029

ABHA NO :

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00 RECEIVED :18/03/2024 11:46:51

REPORTED :18/03/2024 11:46:51

NOT DETECTED

NOT DETECTED

NOT DETECTED

EPITHELIAL CELLS **5-7** 0-5 /HPF

METHOD: MICROSCOPIC EXAMINATION

CASTS

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS

METHOD: MICROSCOPIC EXAMINATION

BACTERIA

METHOD: MICROSCOPIC EXAMINATION

YEAST

DETECTED (FEW)NOT DETECTED

NOT DETECTED

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases

Dr. Akansha Jain Consultant Pathologist Page 13 Of 17





View Details

View Report









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XC001673 PATIENT ID : GOMAF180300251

CLIENT PATIENT ID: 012403180029

ABHA NO

AGE/SEX :24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED : 18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status Results Biological Reference Interval **Final** Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain **Consultant Pathologist**



Page 14 Of 17









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251

CLIENT PATIENT ID: 012403180029

ABHA NO :

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist



Page 15 Of 17

View Details

View Report









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XC001673

PATIENT ID : GOMAF180300251

ABHA NO :

AGE/SEX : 24 Years Female
DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

тз	113.08	60.0 - 181.0	ng/dL
METHOD: CHEMILUMINESCENCE			
T4	7.00	4.5 - 10.9	μg/dL
METHOD: CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1.990	0.550 - 4.780	μIU/mL
METHOD: CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain Consultant Pathologist



Page 16 Of 17



View Report









PATIENT NAME: GOMATI BAI MEENA

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XC001673

PATIENT ID: GOMAF180300251
CLIENT PATIENT ID: 012403180029

ABHA NO :

AGE/SEX : 24 Years Female DRAWN :18/03/2024 11:12:00

RECEIVED :18/03/2024 11:46:51 REPORTED :18/03/2024 16:36:09

Biological Reference Interval Units

Test Report Status	Final	Results
lest kedort Status	Finai	Kesuits

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist






Page 17 Of 17

View Details

View Report







3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563



: Mrs. GOMATI BAI MEENA Name

Age/Gender: 24 Y/Female Patient ID : 012403180029

BarcodeNo : 10118633

Referred By: Self

Registration No: 78004

Registered : 18/Mar/2024 11:12AM

Analysed : 18/Mar/2024 12:43PM

Reported : 18/Mar/2024 12:44PM

Panel : MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

LIVER : Is normal in size, shape and echogenecity.

> The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size

GALL : Is contracted (Post Prandial)

BLADDER

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. SPLEEN : Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Right Kidney:-Size: 92 x 32 mm, Left Kidney:-Size: 96 x 38 mm.

Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal. Pelvi calyceal system is normal.No evidence of hydronephrosis 5.4 mm size calculus seen in mid calyx of right kidney. 4.2 mm size calculus seen in mid calyx of left kidney.

URINARY: Bladder is partially filled as patient not willing to hold urine.

BLADDER: Pre void vol: 83 ml

UTERUS: Uterus and ovaries could not be seen due to partially filled bladder

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

NO evidence of lymphadenopathy or mass lesion in retroperitoneum. Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION:Bilateral renal calculi

*** End Of Report ***

M.B.B.S., D.M.R.D.

RMCNO.005807/14853



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

Name : Mrs. GOMATI BAI MEENA

Age/Gender: 24 Y/Female Patient ID : 012403180029

BarcodeNo: 10118633

Referred By: Self

Registration No: 78004

Registered : 18/Mar/2024 11:12AM

Analysed :

: 18/Mar/2024 02:32PM

Reported

: 18/Mar/2024 02:32PM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

wellness partner

*** End Of Report ***

Page 1 of 2



Dr. Neera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853

ALPL policy mandates the film records to be maintained for a period of 3 months only. Kindly collect the films before this period.



akriti Lahs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563

Name : Mrs. GOMATI BAI MEENA

Age/Gender: 24 Y/Female Patient ID : 012403180029

Referred By: Self

BarcodeNo : 10118633

Registration No: 78004

Registered : 18/Mar/2024 11:12AM

Analysed : 18/Mar/2024 12:43PM

Reported : 18/Mar/2024 12:44PM

Panel MEDI WHEEL (ARCOFEMI HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

LIVER : Is normal in size, shape and echogenecity.

> The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size

GALL : Is contracted (Post Prandial)

BLADDER

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. SPLEEN : Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS

: Right Kidney:-Size: 92 x 32 mm, Left Kidney:-Size: 96 x 38 mm. Bilateral Kidneys are normal in size, shape and echotexture. corticomedullary differentiation is fair and ratio appears normal. Pelvi calyceal system is normal. No evidence of hydronephrosis 5.4 mm size calculus seen in mid calyx of right kidney. 4.2 mm size calculus seen in mid calyx of left kidney.

URINARY: Bladder is partially filled as patient not willing to hold urine.

BLADDER: Pre void vol: 83 ml

UTERUS: Uterus and ovaries could not be seen due to partially filled bladder

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

NO evidence of lymphadenopathy or mass lesion in retroperitoneum. Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Bilateral renal calculi

*** End Of Report ***

Page 1 of

M.B.B.S., D.M.R.D.

RMCNO.005807/14853





Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	MS GOMATI BAI MEENA	AGE	24Y	SEX	FEMALE
REF BY	MEDI WHEEL	DATE	18/03/2024	REG NO	
	ECHOCARE	DIOGRAM RE	PORT		
WINDO	W- POOR/ADEQUATE/GOODVALV	'E			

AORTIC	NORMAL NORMAL	PULMONARY	NORMAL NORMAL	
2D/M-MOD	NOMINAL	POLIVIONANI	NOMIVIAL	

IVSD mm	8.1	IVSS mm	10.8	AORTA mm	20.0
LVID mm	34.2	LVIS mm	19.3	LA mm	24.7
LVPWD mm	8.5	LVPWS mm	12.2	EF%	60%

CHAMBERS

LA	NORMAL	RA	NORMAL
LV	NORMAL	RV	NORMAL
PERICARDIUM	NORMAL		

DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.86/0.59	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s	,400000000	MEAN GRADIANT MmHg	
MVA cm2 (PLANITMETERY)		MVA cm2 (PHT)	
MR		***************************************	

AORTIC

PEAK VELOCITY m/s	1.11	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			

TRICUSPID

PEAK VELOCITY m/s	0.60	PEAK GRADIANT MmHg
MEAN VELOCITY m/s		MEAN GRADIANT MmHg
TR	15/011	PASP mmHg

PULMONARY

PEAK VELOCITY m/s	0.79	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	The state of the s
PR		RVEDP mmHg	

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- **NO RWMA LVEF 60%**
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- **NORMAL VALVULAR ECHO**
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: FAIR LV FUNCTION.